| References: |
MK 0524 is a potent, selective DP1 receptor antagonist with Ki values of 0.57 nM and 0.75 µM For the DP1 and DP2 receptors, respectively. It inhibits PGD2-induced accumulation of cAMP in both washed platelets and platelet-rich plasma with IC50 values of 0.09 and 4.0 nM, respectively. In a sheep model of allergic rhinitis, 0.1 mg/kg MK 0524 completely blocked PGD2-induced nasal congestion. At a dose of 4 mg/kg, MK 0524 suppressed a nicotinic acid-induced vasodilatory response by 80% in a murine model of flushing, an undesirable side-effect of niacin treatment For dyslipidemia. For the detailed information about the solubility of Laropiprant (MK-0524) in water, the solubility of Laropiprant (MK-0524) in DMSO, the solubility of Laropiprant (MK-0524) in PBS buffer, the animal experiment（test） of Laropiprant (MK-0524),the in vivo,in vitro and clinical trial test of Laropiprant (MK-0524),the cell experiment（test） of Laropiprant (MK-0524),the IC50, EC50 and Affinity of Laropiprant (MK-0524), please contact DC Chemicals. |
